RespireRx Pharmaceuticals Inc. (RSPI)

RespireRx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selling, General & Admin	1.09	1.15	1.86	2.68	1.14	1.49
Research & Development	0.31	0.43	0.7	0.64	0.6	0.69
Operating Expenses	1.41	1.58	2.56	3.32	1.74	2.18
Operating Income	-1.41	-1.58	-2.56	-3.32	-1.74	-2.18
Interest Expense	-0.44	-0.6	-0.72	-0.55	-0.4	-0.14
Currency Exchange Gain (Loss)	-0.05	0.05	0.08	-0.05	0.03	-0.11
Other Non Operating Income (Expenses)	-	-	0	-	-	-
EBT Excluding Unusual Items	-1.9	-2.13	-3.21	-3.91	-2.12	-2.43
Other Unusual Items	0.1	0.03	0.06	-0.39	-	-0.17
Pretax Income	-1.8	-2.1	-3.14	-4.3	-2.12	-2.59
Net Income	-1.8	-2.1	-3.14	-4.3	-2.12	-2.59
Preferred Dividends & Other Adjustments	0.37	1.87	0.38	1.44	-	-
Net Income to Common	-2.17	-3.97	-3.52	-5.74	-2.12	-2.59
Shares Outstanding (Basic)	174	111	88	26	0	0
Shares Outstanding (Diluted)	174	111	88	26	0	0
Shares Change (YoY)	63.45%	26.01%	241.69%	6515.27%	16.63%	38.57%
EPS (Basic)	-0.01	-0.04	-0.04	-0.22	-5.41	-7.73
EPS (Diluted)	-0.01	-0.04	-0.04	-0.22	-5.41	-7.73
Free Cash Flow	-0.25	-0.14	-0.96	-0.51	-0.49	-0.43
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.02	-1.25	-1.27
EBITDA	-	-	-	-	-	-2.17
D&A For EBITDA	-	-	-	-	-	0.01
EBIT	-1.41	-1.58	-2.56	-3.32	-1.74	-2.18

Updated Nov 17, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.